Literature DB >> 30306311

Glucocorticoid receptor in cervical cancer: an immunhistochemical analysis.

Bernd Peter Kost1, Susanne Beyer1, Lennard Schröder1, Junyan Zhou1, Doris Mayr2, Christina Kuhn1, Sandra Schulze1, Simone Hofmann1, Sven Mahner1, Udo Jeschke3, Helene Heidegger1.   

Abstract

PURPOSE: Cervical cancer is one of the most frequent cancers in women worldwide. In most of all cases, a persistent HPV infection is the leading cause. HPV-specific sequences are able to bind glucocorticoid receptor (GR). Dexamethasone can increase the activity of early promoters in HPV16 and HPV18 interfering in transcription control of viral oncogenes. The aim of our study was to evaluate glucocorticoid receptor as transcriptional factor in its active form in the nucleus of in cervical cancer cells and to correlate the results with clinical patient specific parameters.
METHODS: A total of 250 paraffin-embedded cervical cancer samples obtained from patients having undergone surgery for cervical cancer were used for the study. The expression of GR was immunhistochemical examined and evaluated by a semi-quantitative scoring. SPSS software was used for the statistical evaluation of staining results and survival analysis of patients with cervical cancer.
RESULTS: GR is frequently expressed in cervical carcinoma tissue in favor of squamous cell carcinoma (SCC). An enhanced expression is correlated with rather small clinical stages. The expression of the GR is correlated with better overall survival and progression-free survival.
CONCLUSIONS: The glucocorticoid receptor is frequently expressed in cervical carcinoma tissue in favor of squamous cell carcinoma. An enhanced expression is correlated with rather small clinical stages. The expression of the analyzed receptor is correlated with better overall survival. Further studies are needed to determine useful treatment targets for glucocorticoid receptor manipulation.

Entities:  

Keywords:  Cervical cancer; Glucocorticoid receptor; Survival

Mesh:

Substances:

Year:  2018        PMID: 30306311     DOI: 10.1007/s00404-018-4928-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  5 in total

1.  Overexpression of glucocorticoid receptor promotes the poor progression and induces cisplatin resistance through p38 MAP kinase in cervical cancer patients.

Authors:  Gwan Hee Han; Hee Yun; Julie Kim; Joon-Yong Chung; Jae-Hoon Kim; Hanbyoul Cho
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

2.  In-vitro antiproliferative efficacy of Abrus precatorius seed extracts on cervical carcinoma.

Authors:  Amritpal Kaur; Yash Sharma; Anoop Kumar; Madhumita P Ghosh; Kumud Bala
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

Review 3.  Stress Hormones: Emerging Targets in Gynecological Cancers.

Authors:  Guoqiang Chen; Lei Qiu; Jinghai Gao; Jing Wang; Jianhong Dang; Lingling Li; Zhijun Jin; Xiaojun Liu
Journal:  Front Cell Dev Biol       Date:  2021-07-09

4.  Medroxyprogesterone Acetate Prevention of Cervical Cancer through Progesterone Receptor in a Human Papillomavirus Transgenic Mouse Model.

Authors:  Seunghan Baik; Fabiola F Mehta; Sang-Hyuk Chung
Journal:  Am J Pathol       Date:  2019-11-12       Impact factor: 4.307

Review 5.  Human Papillomavirus Infection in Head and Neck Squamous Cell Carcinomas: Transcriptional Triggers and Changed Disease Patterns.

Authors:  Nikita Aggarwal; Joni Yadav; Kulbhushan Thakur; Rakhi Bibban; Arun Chhokar; Tanya Tripathi; Anjali Bhat; Tejveer Singh; Mohit Jadli; Ujala Singh; Manoj K Kashyap; Alok C Bharti
Journal:  Front Cell Infect Microbiol       Date:  2020-12-02       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.